Back to top

What Is The Future Of Tissue Microarray?

What Is The Future Of Tissue Microarray?

TMA or Tissue microarray is a collection of tissue samples that are arranged in an array fashion in a single paraffin block. As per the opinion of the leading tissue sample provider BioChain tissue microarray, is a cost-efficient way to carry out multiple analysis of samples for several genetic as well as histological applications.

TMA is the perfect solution, as per the opinion of leading genetic researchers, when it comes to analyzing multiple molecular biological markers both in their nucleic acid as well as protein levels. One should keep this in mind that TMA is relatively new in the field of pathology yet, within a short span in time, it was successful in carving out a niche for itself in the global medical field.

TMA finds extensive use in the study of the different progression phases of tumors, especially when the study needs to be carried out at a single go. It makes TMA a cost-effective, efficient, less labor process when compared to the existing and aging analytical techniques.

What are the reasons for its growth?

The market share for TMA is growing at an exponential rate, the reason one should pay close attention to the factors behind its growth. One of the many factors is already mentioned in the previous section, which is its efficiency as the perfect method to analyze tissue samples at a molecular level for assessment of both prognostic as well as diagnostic markers.

TMA has a lot of applications in oncology as well. It is the staple technique used for:

  • research
  • prognostic oncology, and
  • the discovery of new drugs.

On tops of that, the prevalence of cancer in the world along with several other genetic diseases led to the exponential growth of market share for TMA. Other factors include the sudden surge in drug discovery, development and trials for incurable diseases like cancer, as usual, followed by AIDS and other STDs. Before a drug goes to human trial, it is of utmost importance for the same to be tested on human tissue samples to document its side effects (if any) as well as its overall performance as a possible cure for the disease.

Pharmaceutical companies make sure that they are turning to TMA for their trial drugs as it is a known fact that prototypes are bound to fail in their development stages. That being said, conducting trails on live human tissue samples is an important part of drug discovery and development of both prototypes as well as existing pharmaceutical products. Back in the day, tissue analysis was carried out on a slide-by-slide way which was not only time consuming but also labor intrinsic with chances of human error on an all-time high. With the advent of TMA, costs came down along with the time needed to develop a drug since human error came down to negligible levels.

The fastest growing market in the world for TMA is the Asia Pacific region. The reason behind it is simple, the developing nations in this region like China and India. Both these countries are taking all the necessary steps to improve their healthcare sector. It can be considered as another contributing factor for the growth of TMA which is expected to surpass the growth rate of 10.88% mark by the end of 2023.